Editas Current Deferred Revenue from 2010 to 2024
| EDIT Stock | USD 2.37 0.04 1.66% |
Current Deferred Revenue | First Reported 2014-12-31 | Previous Quarter 14.7 M | Current Value 14.7 M | Quarterly Volatility 20.5 M |
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
Editas | Current Deferred Revenue |
Latest Editas Medicine's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Editas Medicine over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Editas Medicine's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Editas Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 10,074,213 | |
| Geometric Mean | 5,089,087 | |
| Coefficient Of Variation | 86.70 | |
| Mean Deviation | 7,254,074 | |
| Median | 9,454,150 | |
| Standard Deviation | 8,734,597 | |
| Sample Variance | 76.3T | |
| Range | 25.9M | |
| R-Value | 0.55 | |
| Mean Square Error | 57.5T | |
| R-Squared | 0.30 | |
| Significance | 0.03 | |
| Slope | 1,070,447 | |
| Total Sum of Squares | 1068.1T |
Editas Current Deferred Revenue History
About Editas Medicine Financial Statements
Editas Medicine shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 9.5 M | 14.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.